The application of dendritic cell-derived exosomes in tumour immunotherapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 2, 2000, Pages 185-194

  Quah, Ben ^a   O'Neill, Helen C ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; B CELL LYMPHOMA; CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOSOME; EXOCYTOSIS; HUMAN; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR IMMUNITY; VACCINATION; ANIMAL; CD4+ T LYMPHOCYTE; CELL FRACTIONATION; CELL ORGANELLE; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METHODOLOGY; NEOPLASM; TRANSPLANTATION; ULTRASTRUCTURE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL FRACTIONATION; CLINICAL TRIALS; DENDRITIC CELLS; EXOCYTOSIS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; ORGANELLES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034167163     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2000.15.185     Document Type: Review

References (67)

1. Boyle P. The global burden of cancer. Lancet 1997; 349: 23-6.
2. Rennie J and Rustling R. Making headway against cancer. Sc Am 1996;275: 56-9.
3. Boon T, Gerottini JC, Van der Eynde B, Van der Bruggen P and Van Pel A. Tumor antigens recognized by T lymphocytes. Annual Rev Immunol 1994;12: 337-65.
4. Boon T and van der Bruggen P. Human tumor antigens recognised by T lymphocytes. J Exp Med 1996; 183: 725-9.
5. Van den Eynde B, van der Bruggen, and Posert T. (1997). T cell defined antigens. Curr Opin Immunol 1997;9: 684-93.
6. Kershaw MH, Trapani JA, and Smyth MJ. (1995). Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Ther Immunol 1995;2: 173-181.
7. Isaaz S, Baetz K, Olsen K, Podack E, Griffiths G. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur J Immunol 1995;25: 1071-9.
8. Janeway CA and Bottomly K. Signals and signs for lymphocyte responses. Cell 1994;76: 275-85.
9. Ridge JP, Di Rosa F, Matzingerm PA. A conditioned dendritic cell can be a temporal bridge between a CD4+T-helper and a T-killer cell. Nature 1998;393: 474-8.
10. Paul WE and Seder RA. Lymphocyte responses and cytokines. Cell 1994;76: 241-51.
11. Hart D. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90: 3245-87
12. Steinman RM and Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973;137: 1142-62.
13. Shortman K and Caux C. Dendritic cell Development: Multiple Pathways to Nature's Adjuvants. Stem Cells 1997;15: 409-19.
14. Cella M, Sallusto F, and Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9: 10-6.
15. Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, de Saint-Vis B, Jacquet C, Yoneda K, Imamura S, Schmitt D, and Banchereau J. CD34+hematopoietic progenitors from human cord blood differentiate along two independant dendritic cell pathways in response to GM-CSF+TNFα. J Exp Med 1996;184: 695-706.
16. Strunk D, Egger C, Leitner G, Hanau D, and Stingl G. A skin homing molecule defines the Langerhans cell progenitor in human peripheral blood. J Exp Med 1997;185: 1131-6.
17. Wu L, Li C, Shortman K. Thymic dendritic cell precursors: relationship to the T lymphocyte lineage and phenotype of the dendritic cell progeny. J Exp Med 1996;184: 903-8.
18. Fazekas de St. Groth, B. The evolution of self tolerance: a new cell arises to meet the challenge of self reactivity. Immunol Today 1998; 19: 448-54.
19. Ferrerol, Anjuere F, MacDonald H, Ardavin C. In vitro negative selection of viral superantigen-reactive thymocytes by thymic dendritic cells. Blood 1997;90: 1943-51.
20. Banchereau J and Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392: 245-52.
21. Steinman RM, Pack M, Inaba K. Dendritic cells in the T-cell areas of lymphoid organs. Immunol Rev 1997; 156: 25-37.
22. Sallusto F, Cella M, Danieli C, and Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatability complex class II compartment: Downregulation by cytokines and bacterial products. J Exp Med 1995;182: 389-400.
23. Austyn JM. New insight into the mobilisation and phagocytic activity of dendritic cells. J Exp Med 1996;183: 1287-92.
24. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, and Bhardwaj N. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998;188: 1359-68.
25. Cresswell P. Assembly, transport, and function of MHC Class II molecules. Annu Rev Immunol 1994;12: 259-93.
26. Bremnes B, Madsen T, Gedde-Dahl M and Bakke O. An LI and ML motif in the cytoplasmic tail of the MHC-associated invariant chain mediate rapid internalisation. J Cell Sci 1994;107: 2021-32.
27. Weenink SM and Gautam AM. Antigen presentation by MHC class II molecules. Immunol Cell Biol 1997;75: 69-81.
28. Sanderson F, Thomas C, Neefjes J and Trowsdale J. Association between HLA-DM and HLA-DR in vivo. Immunity 1996;4: 87-96.
29. Kleijmeer MJ, Ossevoort MA, van Veen CJ, van Hellemond JJ, Neefjes JJ, Kast WM, Melief CJ, and Geuze HJ. MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells. J Immunol 1995;154: 5715-24.
30. Thery C, Brachet V, Regnault A, Rescigno M, Ricciardi-Castagnoli P, Bonnerot C and Amigorena S. MHC class II transport from the Lysosomal compartments to the cell surface is determined by stable peptite binding, but not by the cytosoloic domains of the a-and b-chains. J Immunol 1998;161: 2113-6.
31. Jondel M, Schirmbeck R and Reimann J. MHC classI-restricted CTL responses to exogenous antigens. Immunity 1996,5: 295-302.
32. Orlowski M. The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry 1990;29: 10289-97.
33. Jackson MR and Peterson PA. Assembly and intracellular transport of MHC class I molecules. Annu Rev Cell Biol 1993;9: 207-35.
34. Degen E and Williams DB. Participation of a novel 88-kD protein in the biogenesis of murine class I histocomparability molecules. J Cell Biol 1991;112: 1099:115.
35. Peters PJ, Neefjes JJ, Oorschot V, Pleogh HL and Geuze HJ. Segregation of MHC class II molecules from MHC class I molecules in the golgi complex for transport to lysosomal compartments. Nature 1991; 349: 669-76.
36. Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, and Watts C. Constitutive macropinocytosis allows TAP-dependant major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunology 1997;27: 280-8.
37. Brossart P and Bevan MJ. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 1997;90: 1594-9.
38. Svensson M and Wick MJ. Classical MHC class I presentation of a bacterial fusion protein by bone marrow-derived dendritic cells. Eur J Immunology 1999;29: 180-8.
39. Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T, and Grabbe S. Generation of tumor immunity by bonemarrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999;162: 168-75.
40. Rescigno M, Citterio S, Thery C, Rittig M, Medaglini D, Pozzi G, Amigorena S, and Ricciardi-Castagnoli P. Bacteria-induced neo-biosynthesis, stabilisation, and surface expression of functional class I molecules in mouse dendritic cells. Proc Natl Acad Sci USA 1998;95: 5229-5234.
41. Rescigno MCW, Delia D, Mutini C, Lutz, M., and Ricciardi-Castagnoli P. Dendritic cell maturation is required for initiation of the immune response. J Leukoc Biol 1997;61: 415-421.
42. Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 1999;189: 447-50.
43. Adema GJ, Hartgers F, Verstraten R, de Vries E, Marland G, Menon S, Foster J, Xu Y, Nooyen P, McClanahan T, Bacon KB, and Figdor CG. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 1997;387: 713-7.
44. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JFAP, and Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393: 478-80.
45. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998;4:594-600.
46. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999;147: 599-610.
47. Kleijmeer MJ, Ossevoort MA., van Veen CJ, van Hellemond JJ, Neefjes JJ, Kast WM, Melief CJ, Geuze HJ. MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells. J Immunol 1995;154: 5715-24.
48. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996; 183: 1161-72.
49. Escola JM, Kleijmeer M.T, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 1998,273: 20121-7.
50. Ellem KA, Schmidt CW, Li CL, Misko I, Kelso A, Sing G, Macdonald G, and O'Rourke MG. The labyrinthine ways of cancer immunotherapy - T cell, tumor cell encounter: "how do I lose thee? Let me count the ways". Adv Cancer Res 1998;75: 203-49.
51. Khanna R. Tumour surveillance: missing peptides and MHC molecules. Immunol Cell Biol 1998;76:20-6.
52. Gabrilovich DI, Cienrnik IF, and Carbone DP. Dendritic cells in antitumour immune response, I. Defective antigen presentation in tumour-bearing hosts. Cell Immunol 1996;170. 101-10.
53. Chen Q, Daniel V, Maher DW and Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994;56: 755-60.
54. Timmerman JM and Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999;50: 507-29.
55. Steinbrink K, Wolfl M, Jonuleit H, Knop J, and Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159: 4772-80.
56. Pardoll D. Cancer vaccines. Nat Med 1998;4: 525-31.
57. KataokaT, Schroter M, Hahne M, Schneider P, Irmler M, Thome M, Froelich C, Tschopp J. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol 1998;161: 3936-42.
58. McLellan AD, Starling GC, and Hart DN. Isolation of human blood dendritic cells by discontinuous Nycodenz gradient centrifugation. J Immunol Methods 1995;184: 81-9.
59. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, and Schuler G. Generation of mature dendritic cells from humanblood. An improved method with special regard to clinical applicability. J Immunol Methods 1996;196: 137-51.
60. Fields RC, Shimizu K and Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998;95: 9482-87.
61. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR and Lotze MT. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183: 87-97.
62. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, DeLeo AB and Lotze MT. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-tumour immunity. Nat Med 1995;1: 1297-302.
63. Hsu F, Benike C, Fagnoni F, Liles T, Czerwinski D, Taidi B, Engleman E, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2: 52-8.
64. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dimmer R, Berg G and Schadendorf D. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nat Med 1998;4: 328-32.
65. Ni K and O'Neill HC. Long-term stromal cultures produce dendritic-like cells. Br J Haematol 1997;97: 710-25.
66. Ni K and O'Neill HC. Haemopoiesis in long term stroma-dependent cultures from lymphoid tissues: Production of cells with myeloid/dendritic characteristics. In vitro Cellular and Molecular Biology 1998;34: 298-307.
67. Ni K and O'Neill HC. Spleen stromal cells support haemopoiesis and in vitro growth of dendritic cells from bone marrow. British Journal of Haematology 1999;105: 58-67.